Swiss biotech Asceneuron raises $100m Series C to advance ASN51, an oral OGA inhibitor, into Phase 2 clinical trials for Alzheimer's treatment.
Swiss biotech Asceneuron raises $100m Series C led by Novo Holdings to progress ASN51, an oral OGA inhibitor, into Phase 2 clinical trials for Alzheimer's treatment. The drug targets tau protein aggregation and aims to slow disease progression. The funds will also support ongoing research and development of therapies for Parkinson's and ALS.
July 16, 2024
5 Articles